Senazodan |
| Catalog No.GC32526 |
Senazodan(MCI 154)은 Ca2+ 증감제이며 PDE III에 대한 억제 효과도 나타냅니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 98326-32-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Senazodan is a Ca2+ sensitiser, and also shows inhibition effect on PDE III.
Senazodan seems to affect directly the actin-myosin crossbridge kinetics, and increase myosin ATPase activity[1]. Senazodan produces a concentration-dependent increase in tension development. Senazodan enhance Ca2+ binding to myofilaments and to purified cardiac troponin C. Senazodan also enhances contractility in guinea-pig papillary muscles by inhibiting PDE III[2].
[1]. Lehtonen LA, et al. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet. 2004;43(3):187-203. [2]. Erhardt L. An emerging role for calcium sensitisation in the treatment of heart failure. Expert Opin Investig Drugs. 2005 Jun;14(6):659-70.
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *